New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine
Atypical antipsychotics (AA) are commonly used to manage drug-induced psychosis (DIP) in parkinsonian patients. In the treatment of schizophrenia, AA’s have been associated with increasing reports of new-onset diabetes mellitus (DM). This study examined the risk of developing new-onset DM among park...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2008-01-01
|
| Series: | Drug Target Insights |
| Subjects: | |
| Online Access: | http://la-press.com/article.php?article_id=630 |
| _version_ | 1819035684176920576 |
|---|---|
| author | Hubert H. Fernandez Katie M. McCown Janet Romrell Martha E. Trieschmann Joseph H. Friedman Charles E. Jacobson IV Michael S. Okun |
| author_facet | Hubert H. Fernandez Katie M. McCown Janet Romrell Martha E. Trieschmann Joseph H. Friedman Charles E. Jacobson IV Michael S. Okun |
| author_sort | Hubert H. Fernandez |
| collection | DOAJ |
| description | Atypical antipsychotics (AA) are commonly used to manage drug-induced psychosis (DIP) in parkinsonian patients. In the treatment of schizophrenia, AA’s have been associated with increasing reports of new-onset diabetes mellitus (DM). This study examined the risk of developing new-onset DM among parkinsonian patients on long-term, low dose quetiapine. Fifty-three parkinsonian subjects (mean age: 71.3 years) taking an average quetiapine dose of 70.5 mg/day (range: 12.5–350 mg/day) for a mean duration of 21.3 months (range 3–61 months) were reviewed. Eight out of 53 subjects carried a diagnosis of DM prior to quetiapine treatment. Four out of 45 patients (8.9%) met criteria for new diagnosis of DM, giving a total prevalence rate of 22.6% (12 out of 53). This prevalence rate of 22.6% was slightly higher than that reported in the aged-matched general population (year 2003 DM prevalence = 17.3% for 65–74 years) but methodological differences could explain the difference. Larger epidemiologic studies will be needed to confirm these results as they could potentially impact a significant number of patients. |
| first_indexed | 2024-12-21T07:53:32Z |
| format | Article |
| id | doaj.art-3f51886844d54f80b48fc0a32db21702 |
| institution | Directory Open Access Journal |
| issn | 1177-3928 |
| language | English |
| last_indexed | 2024-12-21T07:53:32Z |
| publishDate | 2008-01-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Drug Target Insights |
| spelling | doaj.art-3f51886844d54f80b48fc0a32db217022022-12-21T19:11:01ZengAboutScience SrlDrug Target Insights1177-39282008-01-0132729New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term QuetiapineHubert H. FernandezKatie M. McCownJanet RomrellMartha E. TrieschmannJoseph H. FriedmanCharles E. Jacobson IVMichael S. OkunAtypical antipsychotics (AA) are commonly used to manage drug-induced psychosis (DIP) in parkinsonian patients. In the treatment of schizophrenia, AA’s have been associated with increasing reports of new-onset diabetes mellitus (DM). This study examined the risk of developing new-onset DM among parkinsonian patients on long-term, low dose quetiapine. Fifty-three parkinsonian subjects (mean age: 71.3 years) taking an average quetiapine dose of 70.5 mg/day (range: 12.5–350 mg/day) for a mean duration of 21.3 months (range 3–61 months) were reviewed. Eight out of 53 subjects carried a diagnosis of DM prior to quetiapine treatment. Four out of 45 patients (8.9%) met criteria for new diagnosis of DM, giving a total prevalence rate of 22.6% (12 out of 53). This prevalence rate of 22.6% was slightly higher than that reported in the aged-matched general population (year 2003 DM prevalence = 17.3% for 65–74 years) but methodological differences could explain the difference. Larger epidemiologic studies will be needed to confirm these results as they could potentially impact a significant number of patients.http://la-press.com/article.php?article_id=630quetiapinediabetesatypical antipsychoticparkinson’s disease |
| spellingShingle | Hubert H. Fernandez Katie M. McCown Janet Romrell Martha E. Trieschmann Joseph H. Friedman Charles E. Jacobson IV Michael S. Okun New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine Drug Target Insights quetiapine diabetes atypical antipsychotic parkinson’s disease |
| title | New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine |
| title_full | New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine |
| title_fullStr | New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine |
| title_full_unstemmed | New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine |
| title_short | New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine |
| title_sort | new onset diabetes mellitus among parkinsonian patients treated with long term quetiapine |
| topic | quetiapine diabetes atypical antipsychotic parkinson’s disease |
| url | http://la-press.com/article.php?article_id=630 |
| work_keys_str_mv | AT huberthfernandez newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT katiemmccown newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT janetromrell newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT marthaetrieschmann newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT josephhfriedman newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT charlesejacobsoniv newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine AT michaelsokun newonsetdiabetesmellitusamongparkinsonianpatientstreatedwithlongtermquetiapine |